Lab Reports |

Anthrax and Cancer

Tracy Hampton, PhD
JAMA. 2008;299(5):513. doi:10.1001/jama.299.5.513-b.
Text Size: A A A
Published online


A modified anthrax toxin may be an effective cancer therapy, as indicated by studies led by investigators at the National Institutes of Health (Liu S et al. J Biol Chem. 2008;283[1]:529-540).

To give anthrax toxin high tumor specificity, the team developed anthrax toxin variants that require activation by matrix metalloproteinases, proteins that are overproduced in cancer cells.

When the investigators tested a mutated toxin in mice, 100% of the animals tolerated a dose that would otherwise have been lethal. The modified toxin was better at killing melanoma tumors than the natural toxin due to its higher specificity and longer half-life in the blood. The modified toxin also could kill other types of cancer cells, such as those from colon and lung tumors. The investigators found that this anticancer activity largely reflected the indirect targeting of tumor vasculature and angiogenic processes.

Figures in this Article

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview


Place holder to copy figure label and caption

Graphic Jump LocationImage not available.

New research suggests that a modified anthrax toxin has potential as an anticancer therapy.

(Photo credit: Scott Camazine/www.sciencesource.com)



Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles